Original Article
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
N Engl J Med 2005; 352:1749-1759April 28, 2005
- Abstract
Background
Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults. Data on the epidemiology and clinical effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development.
Methods
During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (≥65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions. RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serologic studies.
Results
A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled. A total of 2514 illnesses were evaluated. RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients. RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults. Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups. In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, respectively), and mortality (8 percent and 7 percent, respectively). On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clinical Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.
Conclusions
RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high. An effective RSV vaccine may offer benefits for these adults.
Media in This Article
Table 1
Characteristics of the Study Cohorts.Table 2
Rates of Illness and Infection According to Year of Study.Article Activity
- Article
Respiratory syncytial virus (RSV) was first recognized in 1957 as a cause of bronchiolitis in infants and is the most commonly identified cause of lower respiratory tract infection in young children.1 Mild illness in young adults with reinfection was described and confirmed in subsequent family studies.2,3 However, RSV was not recognized as a potentially serious problem in older adults until the 1970s, when outbreaks of the virus occurred in long-term care facilities.4-7 Since then, additional studies in hospitalized adults have suggested that RSV may be an important cause of illness in community-dwelling elderly people.8,9 Most previous studies used insensitive viral culture or retrospective serologic studies for diagnosis, a practice that led to widely variable assessments of the incidence and effects of the disease. Recent estimates of the disease burden of RSV in adults have been based on mathematical models linking viral activity in children with hospitalization and death in adults,10-14 and Thompson et al. have estimated that RSV accounts for approximately 10,000 deaths annually in the United States in persons over the age of 65 years.14 Although these estimates are useful, their accuracy is confounded by cocirculation of other respiratory viruses with indistinguishable clinical syndromes and is limited by the assumption that viral activity in infants reflects events in elderly populations.15-17 These results have stimulated interest in vaccines and other treatments for RSV in adults.15,18,19 However, additional data regarding virus-specific epidemiology and disease effects, particularly in community-dwelling elderly persons and high-risk adults, are needed before embarking on costly vaccine trials.
Therefore, we identified RSV infections during four consecutive winters in prospective cohorts of community-dwelling elderly people and high-risk adults and in persons hospitalized with acute cardiopulmonary conditions. Identical techniques of diagnosing RSV infection and influenza A were used to assess the disease burden and to provide a direct comparison of RSV infection with influenza A, which is a universally recognized cause of serious disease in the populations mentioned above.
Methods
Study Design
The study spanned four consecutive winters, from late 1999 through early 2003 in Rochester, New York. Three groups of patients were recruited: two prospective cohorts (healthy elderly persons and high-risk adults) and a hospitalized cohort of patients who were admitted each winter with cardiopulmonary illnesses. Enrollees or their guardians provided written informed consent. The University of Rochester Research Subjects Review Board and the Rochester General Hospital Clinical Investigation Committee approved the study.
Enrollment of Prospective Cohorts
Persons who were 65 years of age or older and did not have disabling underlying illnesses (i.e., healthy elderly persons) and persons 21 years of age or older with physician-diagnosed congestive heart failure or chronic pulmonary disease (i.e., high-risk adults) were enrolled in the late summer and fall (from July 15 to November 15) and were followed for a maximum of two winters. To be considered high risk, patients with cardiac disease were required to have at least class II symptoms according to the New York Heart Association's classification, and patients with pulmonary disease were required to have activity-restricting symptoms or use long-term medications.20 Advertisements and mailings were used to recruit patients from health maintenance organizations and from cardiac and pulmonary rehabilitation programs.
At enrollment, data on the patients' demographic status, medical history, and functional performance were recorded. Functional status was assessed with the use of a modified Katz Activities of Daily Living (ADL) Scale and the Instrumental Activities of Daily Living (IADL) Scale.21,22 Baseline blood samples were collected from the prospective groups before the RSV season (from July 15 to November 15) and postseason blood samples were collected the following spring (from April 15 to June 15).
Illness Evaluation
Prospective Cohorts
Patients notified study personnel regarding symptoms of respiratory illness or worsening of baseline cardiopulmonary symptoms from November 15 through April 15 of each year. Symptoms included nasal congestion, sore throat, hoarseness, new or worsening cough, sputum production, and dyspnea with or without fever. During home visits, investigators conducted a physical examination, collected nasopharyngeal swabs and blood samples, and obtained a history of the illness. Four to six weeks later, patients were questioned about their functional status and use of health care services (including telephone consultations, office visits, emergency room visits, and hospitalizations). Events related to the use of health care services were recorded as unique if the events were isolated, whereas the highest level of care was counted if the events were directly related.
Hospital Cohort
During the same surveillance periods, all adults 65 years of age or older or with underlying cardiopulmonary diseases who were admitted to Rochester General Hospital with acute respiratory symptoms were evaluated within 48 hours after admission. Enrollment was performed Monday through Friday, so patients who were admitted on Friday were not eligible. Patients with admission diagnoses of pneumonia (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] codes 480 to 486), upper respiratory infection (ICD-9-CM code 465), bronchitis (ICD-9-CM code 466), influenza (ICD-9-CM code 487), chronic obstructive pulmonary disease (ICD-9-CM codes 490 to 492 and 496), asthma (ICD-9-CM code 493), viral illness (ICD-9-CM code 79.9), or congestive heart failure (ICD-9-CM code 428) were eligible and underwent identical evaluations as prospective cohorts. Patients' functional activity scores before their illness were determined by a review of records of social workers and nurses plus interviews with patients and their families. Patients were followed until discharge from the hospital. Follow-up visits were made at home or in the hospital four to six weeks after the initial assessment to collect data on functional activity and convalescent-phase blood samples.
Laboratory Studies
Samples from nasopharyngeal swabs were inoculated into tubes of HEp-2 cells and rhesus monkey kidney cells within four hours after collection, and the remainder were frozen at –80°C. Cultures were examined daily for cytopathic effects in the clinical microbiology laboratory, and viral growth was confirmed by indirect immunofluorescence with the use of monoclonal antibodies specific for RSV and influenzavirus A and B.
Reverse-transcriptase polymerase chain reaction (RT-PCR) for RSV and influenza was performed on 250-μl aliquots of samples from nasopharyngeal swabs with the use of single-tube nested reactions with primers from the conserved region of the RSV fusion and influenza A matrix genes.23,24 The limit of detection for each assay was 0.1 plaque-forming unit.25 RSV subgroups A and B were identified by a strain-specific RT-PCR assay.26
Enzyme immunoassay was used to measure serum IgG responses to purified RSV glycoproteins according to established methods.27 The serum IgG responses to influenza A and B antigens were determined with the use of whole-cell lysate assays infected with influenzavirus, as previously described.24,28 An increase by a factor of four or more in the IgG titer in response to any RSV antigen or influenza antigen was considered diagnostic.
Definitions of Illness
Symptomatic RSV or influenza infections were defined as illnesses with a positive viral culture, a positive RT-PCR assay, or a diagnostic serologic result. Asymptomatic RSV infection was defined as an increase by a factor of four or more in RSV IgG titers in samples obtained after the winter season as compared with those obtained before the winter season in persons without illness or in asymptomatic intervals between illnesses. Interpretation of the serologic results was occasionally complicated by vaccination. During the four years of the study, the timing of influenza vaccination was highly variable because of vaccine shortages or delays. For illnesses that occurred within four weeks after vaccination, the antibody response alone was not sufficient to define influenza infection. Asymptomatic influenza infection was defined as an antibody rise occurring more than four weeks after vaccination during an illness-free interval.
Statistical Analysis
The chi-square test and Fisher's exact test were used to compare proportions. For data with a normal distribution, means were compared with Student's t-test; for skewed data, the Mann–Whitney test was used. The Poisson regression model and McNemar's test were used to compare the rates of illness and viral infection.29
Results
Populations
A total of 608 healthy elderly persons and 540 high-risk adults were enrolled in the prospective surveillance. During the same period, 1483 hospitalized patients were eligible for study, of whom 1388 (94 percent) agreed to participate. Demographic characteristics and admission diagnoses were not significantly different for those who declined to participate in the study.
Characteristics of the study populations are summarized in Table 1Table 1
Characteristics of the Study Cohorts.. The average age in each group was at least 70 years. Of the high-risk patients, 73 percent were 65 years of age or older, 17 percent were between the ages of 55 and 64 years, and 10 percent were 54 years of age or younger. The percentage of persons with exposure to children was higher in the high-risk group than in either the healthy elderly group or the hospitalized group (P=0.008), although living situations were similar for the three groups (Table 1). There were significantly lower rates of chronic disease and the use of medication in the healthy elderly cohort than in the high-risk and hospitalized groups. Despite having substantial cardiopulmonary disease, the high-risk group was only slightly less functional than the healthy elderly group. In contrast, the hospitalized group had significantly worse functional scores before hospitalization than did both prospective cohorts (P<0.001).Illnesses
During the four winter seasons studied, 2514 cases of illness were evaluated (1043 in prospective patients and 1471 in hospitalized patients). Although the numbers of illnesses in the two prospective groups were similar, rates expressed as cases of illness per 100 person-months were higher in high-risk subjects than in healthy elderly patients because of a greater attrition rate (14.3 cases vs. 10.4, P<0.001; relative risk, 1.39; 95 percent confidence interval, 1.23 to 1.57).
During the four winters, the activity of both influenzavirus A and B varied considerably, whereas annual RSV activity was relatively constant (Table 2Table 2
Rates of Illness and Infection According to Year of Study.). The circulating influenzavirus strains varied considerably during the years of study.30 The 1999–2000 season was dominated by influenzavirus A H3N2 (99.5 percent) in the mid-Atlantic region. During subsequent years, the circulating strains were as follows: 2000–2001, 37 percent influenzavirus A (97 percent H1N1) and 63 percent influenzavirus B; 2001–2002, 88 percent influenzavirus A (98 percent H3N2) and 12 percent influenzavirus B; 2002–2003, 86 percent influenzavirus A (70 percent H1N1) and 14 percent influenzavirus B.RSV infection was identified in 102 cases of illness involving patients in the prospective cohorts and in 142 cases involving hospitalized patients. Influenza A was diagnosed in 44 cases of illness involving patients in the prospective cohorts and in 154 cases involving hospitalized patients (Table 2). Given the low number of influenza B infections, subsequent discussion will be limited to influenza A and RSV infection. RSV infection developed annually in 3 to 7 percent of the healthy elderly group and in 4 to 10 percent of the high-risk group. There was no significant difference in the rates of RSV infection or influenza A among patients in their first year of surveillance as compared with their second year. Two patients in the prospective cohorts had two cases of RSV infection each, and four patients had influenza A and RSV infection at different times. The number of patients with RSV infection in the prospective cohorts was approximately twice that of patients with influenza A (97 vs. 39, P<0.001). There were 1.5 RSV infections per 100 person-months in the high-risk group and 0.9 in the healthy elderly group (P=0.02; relative risk, 1.61; 95 percent confidence interval, 1.09 to 2.39). Influenza A rates were identical in the two prospective cohorts: 0.5 infection per 100 person-months. Despite higher rates of RSV infection in the prospective cohorts, the overall numbers of patients who had RSV infection and influenza in the hospital cohort were similar. Data on the hospital cohort do not include those for patients from the prospective cohorts who were subsequently admitted to the hospital.
Viral Diagnosis
Most illnesses (76 percent) were evaluated with all three diagnostic methods (Table 3Table 3
Diagnostic Tests.). Serum from convalescent patients was not available in 18 percent of cases, and nasal specimens were unobtainable in 6 percent. RSV infection was diagnosed with more than one test in 47 percent of cases, RT-PCR alone was used in 20 percent, and serologic testing alone was used in 33 percent. Eleven hospitalized patients had dual infections and were excluded from clinical analyses (nine patients with both RSV infection and influenza A, one with RSV infection and influenza B, and one with influenza A and influenza B). The RSV strain was group A in 73 cases (45 percent) and group B in 89 (55 percent). Both RSV strains circulated each year without significant differences in the percentages of group A and B viruses among mildly ill outpatients and severely ill hospitalized patients.Clinical Effects of Infection in Prospective Cohorts
Eighty-nine percent of RSV infections were symptomatic in the prospective cohorts. Five patients in the healthy elderly group and six patients in the high-risk group had serologic evidence of infection without reported illnesses. Similarly, 91 percent of patients with influenza were symptomatic. The symptoms and signs of RSV infection and those of influenza were not substantially different (data not shown).
The effects of RSV infection were considerable in both the healthy elderly group and the high-risk group (Table 4Table 4
Infections in Healthy Elderly Patients and High-Risk Patients.). Fifteen percent of patients in the healthy elderly group called their physician and 17 percent made office visits, although none of them required emergency room or inpatient services. The use of medical care was significantly greater in the high-risk group: 23 percent called the doctor, 29 percent made office visits, 9 percent visited the emergency room, and 16 percent required hospitalization. Two high-risk patients with RSV infection (4 percent) died. The mean duration of illness was approximately two weeks in both groups, and 39 percent of patients in the healthy elderly group and 45 percent in the high-risk group were unable to perform the normal activities of daily living for at least one day. The proportion of patients with acute functional impairment was substantially greater in the high-risk group with RSV infection than in the healthy elderly group.Among the healthy elderly patients, influenza A infection generated a greater percentage of office visits than did RSV infection (42 percent vs. 17 percent, P=0.04) and a higher rate of antibiotic use (33 percent vs. 9 percent, P=0.02). Among high-risk patients, the use of medical care was similar in the RSV and influenza A subgroups, although office visits were more common in the influenza A subgroup (60 percent vs. 29 percent, P=0.02). However, because RSV infection occurred more frequently than influenza A, the total number of health care visits (office visits, emergency room visits, and hospitalizations) was similar for the two viruses, at 38 and 30, respectively. Acute functional impairment in the healthy elderly group was also greater with influenza than it was with RSV infection, with 67 percent of patients housebound (P=0.005) and 25 percent confined to bed (P=0.05). None of the patients in the healthy elderly group with influenza were hospitalized or died, whereas 20 percent of high-risk patients were hospitalized.
Clinical Effects of Infection with RSV and Influenza A in Hospitalized Patients
Demographic and clinical characteristics of patients with RSV infection and patients with influenza requiring hospitalization were not significantly different (Table 5Table 5
Illnesses in Hospitalized Patients.). Twelve percent of patients with RSV infection and 10 percent of patients with influenza were residents of long-term care facilities, a finding that was similar to that of the hospital cohort in general (8 percent). The clinical effects of RSV infection and influenza in the hospitalized cohorts were also similar, as assessed by the length of stay; whether the patient had pneumonia, was in intensive care, or required mechanical ventilation; and mortality. The mortality among patients with RSV infection was higher in the group admitted from long-term care facilities (38 percent) than in the group admitted from the community (3 percent, P<0.001), whereas among patients with influenza, there was no significant difference between the two groups. Five percent of patients with RSV infection and 6 percent of patients with influenza required a higher level of care at discharge than at admission. The mean IADL functional scores increased slightly after hospitalization for patients with RSV infection (4.1±4.1 to 4.9±4.0), and a similar trend was observed among patients with influenza. Overall, according to the diagnosis at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.Discussion
This four-year prospective, diagnosis-specific study firmly documents that RSV is an important pathogen in elderly and high-risk adults. Although pediatricians are keenly aware that RSV may cause serious illness in their patients, most internists are less aware of RSV. Given the difficulty with diagnosis in clinical practice and the lack of treatment, this lack of awareness is understandable. However, from a public health perspective, our study shows the substantive disease burden associated with this virus and validates the results of earlier, mathematically derived estimates.
Diagnosis by nested RT-PCR allowed a precise determination of the rates of RSV infection that had not previously been possible. In addition, the use of RT-PCR in this study strengthens the causal link between RSV infection and hospitalization, which can be questioned in serologically based studies. In our study, 61 percent of patients who had an increase in antibodies to RSV also had a positive RT-PCR assay, a finding suggesting that infection occurred shortly before admission. Conversely, since 83 percent of patients with a positive PCR assay for RSV whose serum was tested during convalescence had an immune response, it is unlikely that detectable viral RNA reflects transient colonization.
The annual incidence of RSV infection in the prospective cohorts averaged 5.5 percent and was relatively constant during the four years and nearly twice that of influenza A. The rate of RSV infection in this study was higher than the 3 percent observed by Nicholson and colleagues in elderly adults in the United Kingdom and probably reflects our use of RT-PCR and a more sensitive serologic test.31 It must be recognized that the rate of influenza was probably reduced by the high rate of vaccination in our population. Since immunization is estimated to have an efficacy of approximately 50 percent for the prevention of respiratory illness in elderly persons, influenza cases might have been expected to double without vaccination.32
Almost all RSV infections were symptomatic, and they frequently led to acute functional impairment and to the use of health care services. One quarter of all healthy elderly patients had contact with a health care provider during their illness; nearly half of all high-risk patients sought medical attention, and 16 percent were hospitalized. Although influenza resulted in greater use of health care services by healthy elderly patients than did RSV infection, differences between RSV infection and influenza were less distinct in the high-risk group, with a similar number of hospitalizations for each type of infection during the four years. However, the effect of the circulating influenza strain was clearly seen. During years 2 and 4, when the dominant strain was H1N1 (one not associated with substantial morbidity and mortality in the elderly), hospitalizations for RSV infection outnumbered those for influenza.14,33 In contrast, when H3N2 influenza was prevalent, in years 1 and 3, admissions for influenza were two to three times as common as those for RSV infection. This finding is consistent with other data indicating that infection with influenza H3N2 but not H1N1 results in a more severe illness than does RSV infection.14 In addition, the high rate of vaccination for influenza in our community probably affected the rate of hospitalization. The efficacy of vaccination in reducing the rate of hospitalization from influenza is estimated to be 40 to 50 percent.34,35 Sixty-eight percent of patients who were hospitalized with influenza reported having been vaccinated, as compared with 75 percent of those with RSV infection, a finding that suggests a more modest vaccine effect. However, even if the number of influenza cases were doubled, rates of hospitalization for RSV and influenza would not be dramatically different.
Overall, during the study period, RSV infection accounted for 11 percent of hospitalizations for pneumonia, 11 percent for chronic obstructive pulmonary disease, 5 percent for congestive heart failure, and 7 percent for asthma. According to the National Center for Health Statistics of the Centers for Disease Control and Prevention, in 1999 the numbers of discharges from U.S. hospitals of adults 65 years of age or older for the diagnoses of pneumonia, chronic obstructive pulmonary disease, congestive heart failure, and asthma were 1.3 million, 0.76 million, 2.5 million, and 0.35 million, respectively.36 By applying our rates and adjusting by 50 percent for surveillance during the winter months, RSV infection would account for approximately 177,525 admissions each year. On the basis of our study, which showed that the death rate for hospitalized patients with RSV infection was 8 percent, 14,000 annual deaths would be predicted, a number similar to that estimated by Thompson et al.14 Hospitalization costs alone would exceed $1 billion, an estimate not dissimilar to that made by Han et al.37 Outpatient costs would also probably be substantial given our findings and those of Zambon et al., who reported that up to 18 percent of office visits made by elderly adults for respiratory illnesses during winter were RSV-related.38
In addition to bringing RSV to the attention of internists, our study underscores the continuing importance of yearly influenza epidemics in the expanding elderly and high-risk populations. Programs to improve the efficacy of influenza vaccination and to ensure adequate and timely supplies of vaccine should remain a high priority. However, in order to optimize the reduction in the total burden of viral respiratory disease, we must recognize that other pathogens also contribute to the swell of patients in offices and hospitals during the winter months. The results of this study document the importance of RSV infection in adults and confirm the need for the development of an RSV vaccine for high-risk and elderly adults.
Supported by a grant (R01-AI-45969) from the National Institutes of Health.
Dr. Falsey reports having received consulting fees from Sanofi–Aventis and GlaxoSmithKline and a grant from Sanofi–Aventis. Dr. Walsh reports having received consulting fees from Sanofi–Aventis, Arrow Therapeutics, and Alnylam Pharmaceuticals.
We are indebted to Mary Criddle, R.N., and Anita Gellert, R.N., for evaluations of patients; to Barbara Sikora and Gloria Andolina for technical assistance; to Christine Brower for data management; to the staff and patients at Lifetime Health and Lori Callahan at the Rochester General Hospital Pulmonary Rehabilitation Program for their help in conducting the study; and to Drs. John Treanor and Robert Betts for their thoughtful review of the manuscript.
Source Information
From the Department of Medicine, Rochester General Hospital (A.R.F., P.A.H., M.A.F., E.E.W.) and the Department of Medicine, University of Rochester School of Medicine and Dentistry (A.R.F., E.E.W.) — both in Rochester, N.Y.; and the Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md. (C.C.).
Address reprint requests to Dr. Falsey at the Infectious Diseases Unit, Rochester General Hospital, 1425 Portland Ave., Rochester, NY 14621, or at ann.falsey@viahealth.org.
- References
References
1
Hall CB . Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-1928
Full Text | Web of Science | Medline2
Hall CB ,Geiman JM ,Biggar R ,Kotok DI ,Hogan PM ,Douglas RG Jr . Respiratory syncytial virus infections within families. N Engl J Med 1976;294:414-419
Full Text | Web of Science | Medline3
Johnson KM ,Bloom HH ,Mufson MA ,Chanock RM . Natural infection of adults by respiratory syncytial virus: possible relation to mild upper respiratory disease. N Engl J Med 1962;267:68-72
Full Text | Web of Science | Medline4
Hart RJC . An outbreak of respiratory syncytial virus infection in an old people's home. J Infect 1984;8:259-261
CrossRef | Web of Science | Medline5
Sorvillo FJ ,Huie SF ,Strassburg MA ,Butsumyo A ,Shandera WX ,Fannin SL . An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J Infect 1984;9:252-256
CrossRef | Web of Science | Medline6
Respiratory syncytial virus infection in the elderly 1976-1982. Br Med J (Clin Res Ed) 1983;287:1618-1619
CrossRef | Web of Science | Medline7
Vikerfors T ,Grandien M ,Olcen P . Respiratory syncytial virus infections in adults. Am Rev Respir Dis 1987;136:561-564
CrossRef | Web of Science | Medline8
Falsey AR ,Cunningham CK ,Barker WH , et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995;172:389-394
CrossRef | Web of Science | Medline9
Dowell SF ,Anderson LJ ,Gary HE Jr , et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996;174:456-462
CrossRef | Web of Science | Medline10
Fleming DM ,Cross KW . Respiratory syncytial virus or influenza? Lancet 1993;342:1507-1510
CrossRef | Web of Science | Medline11
Griffin MR ,Coffey CS ,Neuzil KM ,Mitchel EF Jr ,Wright PF ,Edwards KM . Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med 2002;162:1229-1236
CrossRef | Web of Science | Medline12
Nicholson KG . Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 1996;116:51-63
CrossRef | Web of Science | Medline13
Neuzil KM ,Maynard C ,Griffin MR ,Heagerty P . Winter respiratory viruses and health care use: a population-based study in the northwest United States. Clin Infect Dis 2003;37:201-207
CrossRef | Web of Science | Medline14
Thompson WW ,Shay DK ,Weintraub E , et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186
CrossRef | Web of Science | Medline15
Morens DM . Influenza-related mortality: considerations for practice and public health. JAMA 2003;289:227-229
CrossRef | Web of Science | Medline16
McIntosh K ,Kapikian AZ ,Turner HC ,Hartley JW ,Parrott RH ,Chanock RM . Seroepidemiologic studies of coronavirus infection in adults and children. Am J Epidemiol 1970;91:585-592
Web of Science | Medline17
Williams JV ,Harris PA ,Tollefson SJ , et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350:443-450
Full Text | Web of Science | Medline18
La Montagne JR . RSV pneumonia, a community-acquired infection in adults. Lancet 1997;349:149-150
CrossRef | Web of Science | Medline19
Simoes EA . Overlap between respiratory syncytial virus infection and influenza. Lancet 2001;358:1382-1383
CrossRef | Web of Science | Medline20
Management of chronic heart failure. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. Philadelphia: W.B. Saunders, 2001:640-1.
21
Lawton MP . The functional assessment of elderly people. J Am Geriatr Soc 1971;19:465-481
Web of Science | Medline22
Katz S ,Ford AB ,Moskowitz RW ,Jackson BA ,Jaffe MW . Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychological function. JAMA 1963;185:914-919
Web of Science | Medline23
Walsh EE ,Falsey AR ,Swinburne IA ,Formica MA . Reverse transcription polymerase chain reaction (RT-PCR) for diagnosis of respiratory syncytial virus infection in adults: use of a single-tube “hanging droplet“ nested PCR. J Med Virol 2001;63:259-263
CrossRef | Web of Science | Medline24
Walsh EE ,Cox C ,Falsey AR . Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002;50:1498-1503
CrossRef | Web of Science | Medline25
Falsey AR ,Formica MA ,Walsh EE . Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002;40:817-820
CrossRef | Web of Science | Medline26
Falsey AR ,Formica MA ,Treanor JJ ,Walsh EE . Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 2003;41:4160-4165
CrossRef | Web of Science | Medline27
Falsey AR ,Treanor JJ ,Betts RF ,Walsh EE . Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992;40:115-119
Web of Science | Medline28
Harmon MW, Kendal AP. Influenza viruses. In: Schmidt NJ, Emmons RW, eds. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 6th ed. Washington, D.C.: American Public Health Association, 1989:631-68.
29
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:113-6.
30
Centers for Disease Control and Prevention. Influenza season summaries, 1999-2003. (Accessed April 1, 2005, at http://www.cdc.gov/flu/weekly/fluactivity.htm.)
31
Nicholson KG ,Kent J ,Hammersley V ,Cancio E . Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997;315:1060-1064
CrossRef | Web of Science | Medline32
Govaert TME ,Thijs CTMCN ,Masurel N ,Sprenger MJW ,Dinant GJ ,Knottnerus JA . The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994;272:1661-1665
CrossRef | Web of Science | Medline33
Centers for Disease Control and Prevention. Influenza season summary. (Accessed April 1, 2005, at http://www.cdc.gov/flu/weekly/fluactivity.htm.)
34
Nichol KL ,Margolis KL ,Wuorenma J ,Von Sternberg T . The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784
Full Text | Web of Science | Medline35
Foster DA ,Talsma A ,Furumoto-Dawson A , et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307
Web of Science | Medline36
National Center for Health Statistics, Popovic JR. National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Hyattsville, Md.: National Center for Health Statistics, 2001. (DHHS publication no. (PHS) 2001-1722.)
37
Han LL ,Alexander JP ,Anderson LJ . Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999;179:25-30
CrossRef | Web of Science | Medline38
Zambon MC ,Stockton JD ,Clewley JP ,Fleming DM . Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001;358:1410-1416
CrossRef | Web of Science | Medline
- Citing Articles (188)
Citing Articles
1
V. Luchsinger, P. A. Piedra, M. Ruiz, E. Zunino, M. A. Martinez, C. Machado, R. Fasce, M. T. Ulloa, M. C. Fink, P. Lara, L. F. Avendano. (2012) Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus. Clinical Infectious Diseases
CrossRef2
J. L. Grodin, K. S. Wu, E. E. Kitchell, J. Le, J. D. Mishkin, M. H. Drazner, D. W. Markham. (2012) Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient. Case Reports in Cardiology 2012, 1-4
CrossRef3
Janet E. McElhaney, Xin Zhou, H. Keipp Talbot, Ernst Soethout, R. Chris Bleackley, David Granville, Graham Pawelec. (2012) The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine
CrossRef4
Georg Maschmeyer. (2011) Diagnosis and Antimicrobial Therapy of Lung Infiltrates in Febrile Neutropenic Cancer Patients. Current Infectious Disease Reports 13:6, 510-516
CrossRef5
David J. Jackson, Annemarie Sykes, Patrick Mallia, Sebastian L. Johnston. (2011) Asthma exacerbations: Origin, effect, and prevention. Journal of Allergy and Clinical Immunology 128:6, 1165-1174
CrossRef6
Weining Wu, Andrew Macdonald, Julian A. Hiscox, John N. Barr. (2011) Different NF-κB activation characteristics of human respiratory syncytial virus subgroups A and B. Microbial Pathogenesis
CrossRef7
Kristin A Shadman, Ellen R Wald. (2011) A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opinion on Biological Therapy 11:11, 1455-1467
CrossRef8
Muhammad Shafique, Jan Wilschut, Aalzen de Haan. (2011) Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine
CrossRef9
Julia L Hurwitz. (2011) Respiratory syncytial virus vaccine development. Expert Review of Vaccines 10:10, 1415-1433
CrossRef10
Y. Linhart, T. Shohat, M. Bromberg, E. Mendelson, R. Dictiar, M. S. Green. (2011) Excess mortality from seasonal influenza is negligible below the age of 50 in Israel: implications for vaccine policy. Infection 39:5, 399-404
CrossRef11
M.E. García Leoni, B. Macías Bou, L. Martín González, E. Martínez Larrull. (2011) Infecciones respiratorias. Medicine - Programa de Formación Médica Continuada Acreditado 10:88, 5947-5954
CrossRef12
Burke A. Cunha, Uzma Syed, Jean E. Hage. (2011) Respiratory syncytial virus (RSV) community-acquired pneumonia (CAP) in a hospitalized adult with human immunodeficiency virus (HIV) mimicking influenza A and Pneumocystis (carinii) jiroveci pneumonia (PCP). Heart & Lung: The Journal of Acute and Critical Care
CrossRef13
P. HARDELID, N. ANDREWS, R. PEBODY. (2011) Excess mortality monitoring in England and Wales during the influenza A(H1N1) 2009 pandemic. Epidemiology and Infection 139:09, 1431-1439
CrossRef14
Nicola A. Hanania, Monroe J. King, Sidney S. Braman, Carol Saltoun, Robert A. Wise, Paul Enright, Ann R. Falsey, Sameer K. Mathur, Joe W. Ramsdell, Linda Rogers, David A. Stempel, John J. Lima, James E. Fish, Sandra R. Wilson, Cynthia Boyd, Kushang V. Patel, Charles G. Irvin, Barbara P. Yawn, Ethan A. Halm, Stephen I. Wasserman, Mark F. Sands, William B. Ershler, Dennis K. Ledford. (2011) Asthma in the elderly: Current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop. Journal of Allergy and Clinical Immunology 128:3, S4-S24
CrossRef15
Nilay Dey, Tianshuang Liu, Roberto P. Garofalo, Antonella Casola. (2011) TAK1 regulates NF-ΚB and AP-1 activation in airway epithelial cells following RSV infection. Virology 418:2, 93-101
CrossRef16
Peter L. Collins, José A. Melero. (2011) Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Research
CrossRef17
G. Dimopoulos, M. Lerikou, S. Tsiodras, Aik Chranioti, E. Perros, U. Anagnostopoulou, A. Armaganidis, P. Karakitsos. (2011) Viral epidemiology of acute exacerbations of chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics
CrossRef18
Robin Brittain-Long, Lars-Magnus Andersson, Sigvard Olofsson, Magnus Lindh, Johan Westin. (2011) Seasonal variations of 15 respiratory agents illustrated by the application of a multiplex polymerase chain reaction assay. Scandinavian Journal of Infectious Diseases1-9
CrossRef19
Jean-François Bonfanti, Gabriela Ispas, Frans Van Velsen, Wieslawa Olszewska, Tom Gevers, Dirk Roymans. 2011. Discovery of the RSV Inhibitor TMC353121. , 339-352.
CrossRef20
Joanna Chapman, Stuart Cockerill. 2011. Discovery and Development of RSV604. , 367-382.
CrossRef21
Nicholas A. Meanwell, Christopher W. Cianci, Mark R. Krystal. 2011. Discovery and Development of Orally Active RSV Fusion Inhibitors. , 353-366.
CrossRef22
Alexander C Schmidt, Anne Schaap-Nutt, Emmalene J Bartlett, Henrick Schomacker, Jim Boonyaratanakornkit, Ruth A Karron, Peter L Collins. (2011) Progress in the development of human parainfluenza virus vaccines. Expert Review of Respiratory Medicine 5:4, 515-526
CrossRef23
Lauren J. Stockman, Aaron T. Curns, Larry J. Anderson, Gayle Fischer-Langley. (2011) Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997–2006. The Pediatric Infectious Disease Journal1
CrossRef24
Hildenêr Nogueira Lima, Viviane Fongaro Botosso, Danielle Bruna Leal Oliveira, Angélica Cristine de Almeida Campos, Andrea Lima Leal, Tereza Souza Silva, Patrícia Alves Ramos Bosso, Claudia Trigo Pedroso Moraes, Claudionor Gomes da Silva Filho, Sandra Elisabete Vieira, Alfredo Elias Gilio, Klaus Eberhard Stewien, Edison Luiz Durigon. (2011) Molecular epidemiology of the SH (small hydrophobic) gene of human respiratory syncytial virus (HRSV), over 2 consecutive years. Virus Research
CrossRef25
Janet E. McElhaney. (2011) Influenza vaccine responses in older adults. Ageing Research Reviews 10:3, 379-388
CrossRef26
, W. Sánchez-Yebra, J. A. Ávila-Carrillo, F. Giménez-Sánchez, A. Reyes-Bertos, M. Sánchez-Forte, M. Morales-Torres, A. Rojas, J. Mendoza. (2011) Viral agents causing lower respiratory tract infections in hospitalized children: evaluation of the Speed-Oligo® RSV assay for the detection of respiratory syncytial virus. European Journal of Clinical Microbiology & Infectious Diseases
CrossRef27
Yung-Hung Luo, Chu-Yun Huang, Kuang-Yao Yang, Yu-Chin Lee. (2011) Tratamiento con ribavirina inhalada en el síndrome de dificultad respiratoria aguda inducida por virus respiratorio sincitial en el adulto. Archivos de Bronconeumología 47:6, 315-317
CrossRef28
Yung-Hung Luo, Chu-Yun Huang, Kuang-Yao Yang, Yu-Chin Lee. (2011) Inhaled Ribavirin Therapy in Adult Respiratory Syncytial Virus-Induced Acute Respiratory Distress Syndrome. Archivos de Bronconeumología (English Edition) 47:6, 315-317
CrossRef29
S. Sethi. (2011) Molecular Diagnosis of Respiratory Tract Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases 52:Supplement 4, S290-S295
CrossRef30
Susana Infantes, Elena Lorente, Juan José Cragnolini, Manuel Ramos, Ruth García, Mercedes Jiménez, Salvador Iborra, Margarita Del Val, Daniel López. (2011) Unusual viral ligand with alternative interactions is presented by HLA-Cw4 in human respiratory syncytial virus-infected cells. Immunology and Cell Biology 89:4, 558-565
CrossRef31
Maria L Felix, Claudia V Guerra, Miguel A Hinojosa, Clarita I Cabezas, Ricardo Hidalgo, Diana H Samaniego, Susana Nicola, Maria L Felix. 2011. Vaccines for the common cold. .
CrossRef32
Olli Ruuskanen, Elina Lahti, Lance C Jennings, David R Murdoch. (2011) Viral pneumonia. The Lancet 377:9773, 1264-1275
CrossRef33
N. G. Papadopoulos, I. Christodoulou, G. Rohde, I. Agache, C. Almqvist, A. Bruno, S. Bonini, L. Bont, A. Bossios, J. Bousquet, F. Braido, G. Brusselle, G. W. Canonica, K. H. Carlsen, P. Chanez, W. J. Fokkens, M. Garcia-Garcia, M. Gjomarkaj, T. Haahtela, S. T. Holgate, S. L. Johnston, G. Konstantinou, M. Kowalski, A. Lewandowska-Polak, K. Lødrup-Carlsen, M. Mäkelä, I. Malkusova, J. Mullol, A. Nieto, E. Eller, C. Ozdemir, P. Panzner, T. Popov, S. Psarras, E. Roumpedaki, M. Rukhadze, A. Stipic-Markovic, A. Todo Bom, E. Toskala, P. van Cauwenberge, C. van Drunen, J. B. Watelet, M. Xatzipsalti, P. Xepapadaki, T. Zuberbier. (2011) Viruses and bacteria in acute asthma exacerbations - A GA2LEN-DARE* systematic review. Allergy 66:4, 458-468
CrossRef34
Melvin Wright, Giovanni Piedimonte. (2011) Respiratory syncytial virus prevention and therapy: Past, present, and future. Pediatric Pulmonology 46:4, 324-347
CrossRef35
Emily H. Chan, Robyn Tamblyn, Katia M.L. Charland, David L. Buckeridge. (2011) Outpatient physician billing data for age and setting specific syndromic surveillance of influenza-like illnesses. Journal of Biomedical Informatics 44:2, 221-228
CrossRef36
Debby Kruijsen, Marcel A. Schijf, Michaël V. Lukens, Nathalie O. van Uden, Jan L. Kimpen, Frank E. Coenjaerts, Grada M. van Bleek. (2011) Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine 29:15, 2730-2741
CrossRef37
William P. Goins, H. Keipp Talbot, Thomas R. Talbot. (2011) Health Care–Acquired Viral Respiratory Diseases. Infectious Disease Clinics of North America 25:1, 227-244
CrossRef38
H. K. Talbot, M. R. Griffin, Q. Chen, Y. Zhu, J. V. Williams, K. M. Edwards. (2011) Effectiveness of Seasonal Vaccine in Preventing Confirmed Influenza-Associated Hospitalizations in Community Dwelling Older Adults. Journal of Infectious Diseases 203:4, 500-508
CrossRef39
Jianou Qiao, Ang Li, Xianqiao Jin. (2011) TSLP from RSV-stimulated rat airway epithelial cells activates myeloid dendritic cells. Immunology and Cell Biology 89:2, 231-238
CrossRef40
Mika Rämet, Matti Korppi, Mikko Hallman. (2011) Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making?. Pediatric Pulmonology 46:2, 101-110
CrossRef41
Chantel Sloan, Martin L. Moore, Tina Hartert. (2011) Impact of Pollution, Climate, and Sociodemographic Factors on Spatiotemporal Dynamics of Seasonal Respiratory Viruses. Clinical and Translational Science 4:1, 48-54
CrossRef42
S. S. Hernes, H. Quarsten, E. Hagen, A. L. Lyngroth, A. H. Pripp, B. Bjorvatn, P. S. Bakke. (2011) Swabbing for respiratory viral infections in older patients: a comparison of rayon and nylon flocked swabs. European Journal of Clinical Microbiology & Infectious Diseases 30:2, 159-165
CrossRef43
Barney S. Graham. (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunological Reviews 239:1, 149-166
CrossRef44
Annemieke Schuurhof, Riny Janssen, Hanneke de Groot, Hennie M Hodemaekers, Arja de Klerk, Jan LL Kimpen, Louis Bont. (2011) Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. Respiratory Research 12:1, 121
CrossRef45
Leonard R Krilov. (2011) Respiratory syncytial virus disease: update on treatment and prevention. Expert Review of Anti-infective Therapy 9:1, 27-32
CrossRef46
A. G. Telcian, V. Laza-Stanca, M. R. Edwards, J. A. Harker, H. Wang, N. W. Bartlett, P. Mallia, M. T. Zdrenghea, T. Kebadze, A. J. Coyle, P. J. M. Openshaw, L. A. Stanciu, S. L. Johnston. (2011) RSV-Induced Bronchial Epithelial Cell PD-L1 Expression Inhibits CD8+ T Cell Nonspecific Antiviral Activity. Journal of Infectious Diseases 203:1, 85-94
CrossRef47
Xiaoyong Bao, Hemalatha Indukuri, Tianshuang Liu, Sui-Ling Liao, Bing Tian, Allan R. Brasier, Roberto P. Garofalo, Antonella Casola. (2010) IKKε modulates RSV-induced NF-κB-dependent gene transcription. Virology 408:2, 224-231
CrossRef48
Xiaohong Liu, Xiaohua Stella Huang, Ny Sin, Brian L. Venables, Vikram Roongta. (2010) 15N chemical shifts of a series of isatin oxime ethers and their corresponding nitrone isomers. Magnetic Resonance in Chemistry 48:11, 873-876
CrossRef49
Terianne Wong, Gary Hellermann, Shyam Mohapatra. (2010) The Infectious March: The Complex Interaction Between Microbes and the Immune System in Asthma. Immunology and Allergy Clinics of North America 30:4, 453-480
CrossRef50
Blair D. Westerly, R. Stokes Peebles. (2010) Respiratory Syncytial Virus Infections in the Adult Asthmatic – Mechanisms of Host Susceptibility and Viral Subversion. Immunology and Allergy Clinics of North America 30:4, 523-539
CrossRef51
Carole Buecher, Sek Mardy, Wei Wang, Veasna Duong, Sirenda Vong, Monica Naughtin, Astrid Vabret, François Freymuth, Vincent Deubel, Philippe Buchy. (2010) Use of a multiplex PCR/RT-PCR approach to assess the viral causes of influenza-like illnesses in Cambodia during three consecutive dry seasons. Journal of Medical Virology 82:10, 1762-1772
CrossRef52
Dirk Roymans, Anil Koul. (2010) Respiratory syncytial virus: a prioritized or neglected target?. Future Medicinal Chemistry 2:10, 1523-1527
CrossRef53
Christelle Kassis, Richard E. Champlin, Ray Y. Hachem, Chitra Hosing, Jeffrey J. Tarrand, Cheryl A. Perego, Joyce L. Neumann, Issam I. Raad, Roy F. Chemaly. (2010) Detection and Control of a Nosocomial Respiratory Syncytial Virus Outbreak in a Stem Cell Transplantation Unit: The Role of Palivizumab. Biology of Blood and Marrow Transplantation 16:9, 1265-1271
CrossRef54
Helmar C Lehmann, Hans-Peter Hartung, Bernd C Kieseier, Richard AC Hughes. (2010) Guillain-Barré syndrome after exposure to influenza virus. The Lancet Infectious Diseases 10:9, 643-651
CrossRef55
Toon Stegmann, Tobias Kamphuis, Tjarko Meijerhof, Ellen Goud, Aalzen de Haan, Jan Wilschut. (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 28:34, 5543-5550
CrossRef56
Weifeng Song, Shipeng Wei, Sadis Matalon. (2010) Inhibition of epithelial sodium channels by respiratory syncytial virus in vitro and in vivo. Annals of the New York Academy of Sciences 1203:1, 79-84
CrossRef57
Yoshihiko Murata, Paula M. Lightfoote, Jamie N. Biear, Ann R. Falsey, Edward E. Walsh. (2010) Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine 28:38, 6242-6246
CrossRef58
Barbara Monika Hauptmeier, Irmgard Borg, Gernot Rohde, Agnes Anders, Juliane Kronsbein, Sören Gatermann, Albrecht Bufe, Torsten Blum, Gerhard Schultze-Werninghaus, Torsten Thomas Bauer. (2010) Viral colonization in intubated patients: initial pathogen pattern and follow-up. The Clinical Respiratory Journal 4:3, 139-146
CrossRef59
Junya Tanaka, Kazuyuki Saga, Masahiro Kido, Hisayo Nishiura, Takuji Akamatsu, Tsutomu Chiba, Norihiko Watanabe. (2010) Proinflammatory Th2 Cytokines Induce Production of Thymic Stromal Lymphopoietin in Human Colonic Epithelial Cells. Digestive Diseases and Sciences 55:7, 1896-1904
CrossRef60
Jesse Papenburg, Guy Boivin. (2010) The distinguishing features of human metapneumovirus and respiratory syncytial virus. Reviews in Medical Virology 20:4, 245-260
CrossRef61
Joann M. Lau, Schuyler S. Korban. (2010) Transgenic apple expressing an antigenic protein of the human respiratory syncytial virus. Journal of Plant Physiology 167:11, 920-927
CrossRef62
P. Subbarayan, H. Qin, S. Pillai, J. J. Lee, A. P. Pfendt, G. Willing, M. E. Miller, V. A. Dennis, S. R. Singh. (2010) Expression and characterization of a multivalent human respiratory syncytial virus protein. Molecular Biology 44:3, 420-430
CrossRef63
Alberto F. Maffey, Paola R. Barrero, Carolina Venialgo, Francisco Fernández, Valentina A. Fuse, Mariana Saia, Analía Villalba, Marcelo Rodríguez Fermepin, Alejandro M. Teper, Alicia S. Mistchenko. (2010) Viruses and atypical bacteria associated with asthma exacerbations in hospitalized children. Pediatric Pulmonology 45:6, 619-625
CrossRef64
Sumanta Mukherjee, Nicholas W Lukacs. (2010) Association of IL-13 in respiratory syncytial virus-induced pulmonary disease: still a promising target. Expert Review of Anti-infective Therapy 8:6, 617-621
CrossRef65
J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, A. Vaishnaw. (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences 107:19, 8800-8805
CrossRef66
Mbayame Ndiaye Niang, Ousmane M. Diop, Fatoumata Diene Sarr, Deborah Goudiaby, Hubert Malou-Sompy, Kader Ndiaye, Astrid Vabret, Laurence Baril. (2010) Viral etiology of respiratory infections in children under 5 years old living in tropical rural areas of Senegal: The EVIRA project. Journal of Medical Virology 82:5, 866-872
CrossRef67
Miguel Ángel Rico, Susana Infantes, Manuel Ramos, Alfonsina Trento, Carolina Johnstone, José Antonio Melero, Margarita Del Val, Daniel López. (2010) TLR4-Independent upregulation of activation markers in mouse B lymphocytes infected by HRSV. Molecular Immunology 47:9, 1802-1807
CrossRef68
Stephen E Lapinsky. (2010) Epidemic viral pneumonia. Current Opinion in Infectious Diseases 23:2, 139-144
CrossRef69
A. Pierangeli, C. Scagnolari, M. Gentile, M. T. Spina, A. Iudicello, G. Bertazzoni, G. Antonelli. (2010) Virological diagnosis of respiratory virus infection in patients attending an emergency department during the influenza season. Clinical Microbiology and Infection 16:4, 391-393
CrossRef70
Ann R. Falsey, Patricia A. Hennessey, Maria A. Formica, Mary M. Criddle, Jamie M. Biear, Edward E. Walsh. (2010) Humoral immunity to human metapneumovirus infection in adults. Vaccine 28:6, 1477-1480
CrossRef71
M. Numata, H. W. Chu, A. Dakhama, D. R. Voelker. (2010) From the Cover: Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proceedings of the National Academy of Sciences 107:1, 320-325
CrossRef72
Monroe James King, Nicola A Hanania. (2010) Asthma in the elderly: current knowledge and future directions. Current Opinion in Pulmonary Medicine 16:1, 55-59
CrossRef73
Junaidah B Barnett, Davidson H Hamer, Simin N Meydani. (2010) Low zinc status: a new risk factor for pneumonia in the elderly?. Nutrition Reviews 68:1, 30-37
CrossRef74
Francisco Sanz Herrero, Nuria Marina Malanda, Beatriz Montull Veiga, María Pilar Sanjuán López. (2010) Nuevos retos en la neumonía comunitaria. Archivos de Bronconeumología 46, 22-26
CrossRef75
Elena N. Naumova, Sara M. Parisi, Denise Castronovo, Manisha Pandita, Julia Wenger, Paula Minihan. (2009) Pneumonia and Influenza Hospitalizations in Elderly People with Dementia. Journal of the American Geriatrics Society 57:12, 2192-2199
CrossRef76
Ross B Fulton, Steven M Varga. (2009) Effects of aging on the adaptive immune response to respiratory virus infections. Aging Health 5:6, 775-787
CrossRef77
Gaston De Serres, Noël Lampron, Jacques La Forge, Isabelle Rouleau, Jean Bourbeau, Karl Weiss, Béatrice Barret, Guy Boivin. (2009) Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. Journal of Clinical Virology 46:2, 129-133
CrossRef78
Lone Simonsen, Cecile Viboud, Robert J. Taylor, Mark A. Miller, Lisa Jackson. (2009) Influenza vaccination and mortality benefits: New insights, new opportunities. Vaccine 27:45, 6300-6304
CrossRef79
Ahmed Sabbah, Te Hung Chang, Rosalinda Harnack, Victoria Frohlich, Kaoru Tominaga, Peter H Dube, Yan Xiang, Santanu Bose. (2009) Activation of innate immune antiviral responses by Nod2. Nature Immunology 10:10, 1073-1080
CrossRef80
Joanne M. Langley, Valerie Sales, Allison McGeer, Roland Guasparini, Gerald Predy, William Meekison, Minran Li, Jose Capellan, Elaine Wang. (2009) A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age. Vaccine 27:42, 5913-5919
CrossRef81
Magali Lemaitre, Thierry Meret, Monique Rothan-Tondeur, Joel Belmin, Jean-Louis Lejonc, Laurence Luquel, François Piette, Michel Salom, Marc Verny, Jean-Marie Vetel, Pierre Veyssier, Fabrice Carrat. (2009) Effect of Influenza Vaccination of Nursing Home Staff on Mortality of Residents: A Cluster-Randomized Trial. Journal of the American Geriatrics Society 57:9, 1580-1586
CrossRef82
Georg Maschmeyer, Thomas Beinert, Dieter Buchheidt, Oliver A. Cornely, Hermann Einsele, Werner Heinz, Claus Peter Heussel, Christoph Kahl, Michael Kiehl, Joachim Lorenz, Herbert Hof, Gloria Mattiuzzi. (2009) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. European Journal of Cancer 45:14, 2462-2472
CrossRef83
Aimee K. Zaas, Minhua Chen, Jay Varkey, Timothy Veldman, Alfred O. Hero, Joseph Lucas, Yongsheng Huang, Ronald Turner, Anthony Gilbert, Robert Lambkin-Williams, N. Christine Øien, Bradly Nicholson, Stephen Kingsmore, Lawrence Carin, Christopher W. Woods, Geoffrey S. Ginsburg. (2009) Gene Expression Signatures Diagnose Influenza and Other Symptomatic Respiratory Viral Infections in Humans. Cell Host & Microbe 6:3, 207-217
CrossRef84
Arnold S. Monto, Filippo Ansaldi, Richard Aspinall, Janet E. McElhaney, Luis F. Montaño, Kristin L. Nichol, Joan Puig-Barberà, Joe Schmitt, Iain Stephenson. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27:37, 5043-5053
CrossRef85
Ny Sin, Brian L. Venables, Keith D. Combrink, H. Belgin Gulgeze, Kuo-Long Yu, Rita L. Civiello, Jan Thuring, X. Alan Wang, Zheng Yang, Lisa Zadjura, Anthony Marino, Kathleen F. Kadow, Christopher W. Cianci, Junius Clarke, Eugene V. Genovesi, Ivette Medina, Lucinda Lamb, Mark Krystal, Nicholas A. Meanwell. (2009) Respiratory syncytial virus fusion inhibitors. Part 7: Structure–activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorganic & Medicinal Chemistry Letters 19:16, 4857-4862
CrossRef86
Masanori Asada, Motoki Yoshida, Tomoko Suzuki, Yukimasa Hatachi, Takahiko Sasaki, Hiroyasu Yasuda, Katsutoshi Nakayama, Hidekazu Nishimura, Ryoichi Nagatomi, Hiroshi Kubo, Mutsuo Yamaya. (2009) Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Research 83:2, 191-200
CrossRef87
Christine M. Oshansky, Thomas M. Krunkosky, Jamie Barber, Les P. Jones, Ralph A. Tripp. (2009) Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway. Viral Immunology 22:3, 147-161
CrossRef88
Miguel Ángel Rico, Alfonsina Trento, Manuel Ramos, Carolina Johnstone, Margarita Del Val, José Antonio Melero, Daniel López. (2009) Human respiratory syncytial virus infects and induces activation markers in mouse B lymphocytes. Immunology and Cell Biology 87:4, 344-350
CrossRef89
Janet E McElhaney. (2009) Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Review of Vaccines 8:5, 593-606
CrossRef90
Maria Angeles Marcos, Mariano Esperatti, Antoni Torres. (2009) Viral pneumonia. Current Opinion in Infectious Diseases 22:2, 143-147
CrossRef91
Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long-Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Journal of the American Geriatrics Society 57:3, 375-394
CrossRef92
L. Brett Caram, Jodi Chen, E. William Taggart, David R. Hillyard, Rosemary She, Christopher R. Polage, Jack Twersky, Kenneth Schmader, Cathy A. Petti, Christopher W. Woods. (2009) Respiratory Syncytial Virus Outbreak in a Long-Term Care Facility Detected Using Reverse Transcriptase Polymerase Chain Reaction: An Argument for Real-Time Detection Methods. Journal of the American Geriatrics Society 57:3, 482-485
CrossRef93
Anand C. Patel, Tom J. Brett, Michael J. Holtzman. (2009) The Role of CLCA Proteins in Inflammatory Airway Disease. Annual Review of Physiology 71:1, 425-449
CrossRef94
Christopher M. Evans, Ja Seok Koo. (2009) Airway mucus: The good, the bad, the sticky. Pharmacology & Therapeutics 121:3, 332-348
CrossRef95
C. Steininger, M. Redlberger, W. Graninger, M. Kundi, T. Popow-Kraupp. (2009) Near-patient assays for diagnosis of influenza virus infection in adult patients. Clinical Microbiology and Infection 15:3, 267-273
CrossRef96
Virginia Amanatidou, Stavros Apostolakis, Demetrios A. Spandidos. (2009) Genetic Diversity of the Host and Severe Respiratory Syncytial Virus-Induced Lower Respiratory Tract Infection. The Pediatric Infectious Disease Journal 28:2, 135-140
CrossRef97
Kevin P. High, Suzanne F. Bradley, Stefan Gravenstein, David R. Mehr, Vincent J. Quagliarello, Chesley Richards, Thomas T. Yoshikawa. (2009) Clinical Practice Guideline for the Evaluation of Fever and Infection in Older Adult Residents of Long‐Term Care Facilities: 2008 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48:2, 149-171
CrossRef98
Allison J. McGeer. (2009) Diagnostic Testing or Empirical Therapy for Patients Hospitalized with Suspected Influenza: What to Do?. Clinical Infectious Diseases 48:S1, S14-S19
CrossRef99
R.E. Sarmiento, C.F. Arias, E. Méndez, B. Gómez. (2009) Characterization of a persistent respiratory syncytial virus showing a low-fusogenic activity associated to an impaired F protein. Virus Research 139:1, 39-47
CrossRef100
Georgiana Georgescu, Roy F Chemaly. (2009) Palivizumab: where to from here?. Expert Opinion on Biological Therapy 9:1, 139-147
CrossRef101
Jonas W. Perez, Frederick R. Haselton, David W. Wright. (2009) Viral detection using DNA functionalized gold filaments. The Analyst 134:8, 1548
CrossRef102
Sanjay Sethi. 2009. Antibiotics. , 663-676.
CrossRef103
Janet E McElhaney. (2008) Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging Health 4:6, 603-613
CrossRef104
Carlos A. Camargo, Adit A. Ginde, Sunday Clark, Charles P. Cartwright, Ann R. Falsey, Dennis E. Niewoehner. (2008) Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Internal and Emergency Medicine 3:4, 355-359
CrossRef105
Hayley See, Peter Wark. (2008) Innate immune response to viral infection of the lungs. Paediatric Respiratory Reviews 9:4, 243-250
CrossRef106
Tuomas Jartti, Laura Jartti, Ville Peltola, Matti Waris, Olli Ruuskanen. (2008) Identification of Respiratory Viruses in Asymptomatic Subjects. The Pediatric Infectious Disease Journal 27:12, 1103-1107
CrossRef107
Sethi, Sanjay, Murphy, Timothy F., . (2008) Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 359:22, 2355-2365
Full Text108
Terence E. McManus, Anne-Marie Marley, Noreen Baxter, Sharon N. Christie, Hugh J. O'Neill, J. Stuart Elborn, Peter V. Coyle, Joseph C. Kidney. (2008) Respiratory viral infection in exacerbations of COPD. Respiratory Medicine 102:11, 1575-1580
CrossRef109
Ann R. Falsey, Edward E. Walsh, Jose Capellan, Stefan Gravenstein, Maria Zambon, Eddy Yau, Geoffrey J. Gorse, Robert Edelman, Frederick G. Hayden, Janet E. McElhaney, Kathleen M. Neuzil, Kristen L. Nichol, Eric A. F. Simões, Peter F. Wright, Valérie M.‐P. Sales. (2008) Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High‐Risk Elderly Individuals. The Journal of Infectious Diseases 198:9, 1317-1326
CrossRef110
J. Gaillat, G. Dennetière, E. Raffin-Bru, M. Valette, M.C. Blanc. (2008) Summer influenza outbreak in a home for the elderly: application of preventive measures. Journal of Hospital Infection 70:3, 272-277
CrossRef111
Miquel Falguera. (2008) Pharmacotherapy of pneumonia occurring in older patients. Expert Opinion on Pharmacotherapy 9:16, 2867-2879
CrossRef112
Samson S.Y. WONG, Kwok-Yung YUEN. (2008) Antiviral therapy for respiratory tract infections. Respirology
CrossRef113
Rangaraj Selvarangan, David Abel, Marilyn Hamilton. (2008) Comparison of BD Directigen™ EZ RSV and Binax NOW® RSV tests for rapid detection of respiratory syncytial virus from nasopharyngeal aspirates in a pediatric population. Diagnostic Microbiology and Infectious Disease 62:2, 157-161
CrossRef114
Tina E Faber, Jan LL Kimpen, Louis J Bont. (2008) Respiratory syncytial virus bronchiolitis: prevention and treatment. Expert Opinion on Pharmacotherapy 9:14, 2451-2458
CrossRef115
Markus B. Sikkel, Jennifer K. Quint, Patrick Mallia, Jadwiga A. Wedzicha, Sebastian L. Johnston. (2008) Respiratory Syncytial Virus Persistence in Chronic Obstructive Pulmonary Disease. The Pediatric Infectious Disease Journal 27:Supplement, S63-S70
CrossRef116
Matthew R Olson, Steven M Varga. (2008) Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Review of Vaccines 7:8, 1239-1255
CrossRef117
Angelique G.S.C. Jansen, Elisabeth A.M. Sanders, Kristin L. Nichol, Anton M. van Loon, Arno W. Hoes, Eelko Hak. (2008) Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program. Vaccine 26:44, 5567-5574
CrossRef118
Hoyin Mok, Sujin Lee, David W. Wright, James E. Crowe. (2008) Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine 26:37, 4775-4782
CrossRef119
Elaine M Castilow, Steven M Varga. (2008) Overcoming T-cell-mediated immunopathology to achieve safe respiratory syncytial virus vaccination. Future Virology 3:5, 445-454
CrossRef120
S. M. Castro, D. Kolli, A. Guerrero-Plata, R. P. Garofalo, A. Casola. (2008) Cigarette Smoke Condensate Enhances Respiratory Syncytial Virus-Induced Chemokine Release by Modulating NF-kappa B and Interferon Regulatory Factor Activation. Toxicological Sciences 106:2, 509-518
CrossRef121
Edward A Belongia, David K Shay. (2008) Influenza vaccine for community-acquired pneumonia. The Lancet 372:9636, 352-354
CrossRef122
Angelique G.S.C. Jansen, Elisabeth A.M. Sanders, Jacco Wallinga, Eelke J. Groen, Anton M. van Loon, Arno W. Hoes, Eelko Hak. (2008) Rate-difference method proved satisfactory in estimating the influenza burden in primary care visits. Journal of Clinical Epidemiology 61:8, 803-812
CrossRef123
Hana M El Sahly, Wendy A Keitel. (2008) Clinical data on Fluarix ® : an inactivated split seasonal influenza vaccine. Expert Review of Vaccines 7:6, 713-719
CrossRef124
D. M. FLEMING, A. J. ELLIOT. (2008) Lessons from 40 years' surveillance of influenza in England and Wales. Epidemiology and Infection 136:07,
CrossRef125
Shen-Hao Lai, David A Stein, Antonieta Guerrero-Plata, Sui-Ling Liao, Teodora Ivanciuc, Chao Hong, Patrick L Iversen, Antonella Casola, Roberto P Garofalo. (2008) Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in Mice. Molecular Therapy 16:6, 1120-1128
CrossRef126
Yoshihiko Murata. (2008) Respiratory syncytial virus infection in adults. Current Opinion in Pulmonary Medicine 14:3, 235-240
CrossRef127
Nicole G. Hansbro, Jay C. Horvat, Peter A. Wark, Philip M. Hansbro. (2008) Understanding the mechanisms of viral induced asthma: New therapeutic directions. Pharmacology & Therapeutics 117:3, 313-353
CrossRef128
Alex J Elliot, Douglas M Fleming. (2008) Influenza and respiratory syncytial virus in the elderly. Expert Review of Vaccines 7:2, 249-258
CrossRef129
L. Hobson, M. L. Everard. (2008) Persistent of respiratory syncytial virus in human dendritic cells and influence of nitric oxide. Clinical & Experimental Immunology 151:2, 359-366
CrossRef130
Francisco López-Medrano, José María Aguado. (2008) Virus respiratorios: los más frecuentes, los más olvidados. Enfermedades Infecciosas y Microbiología Clínica 26:2, 67-68
CrossRef131
Janet E McElhaney. (2008) Influenza vaccination in the elderly as a strategy to improve vaccine effectiveness. Aging Health 4:1, 33-35
CrossRef132
Dena L. Schanzer, Joanne M. Langley, Theresa W.S. Tam. (2008) Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza and Other Respiratory Viruses 2:1, 1-8
CrossRef133
Félix Gutiérrez, Mar Masiá. (2008) Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. Drugs & Aging 25:7, 585-610
CrossRef134
Robert J Taylor, Lone Simonsen. (2008) Breaking through to daylight: new opportunities for influenza control. Future Virology 3:1, 7-11
CrossRef135
L. M. Pletneva, O. Haller, D. D. Porter, G. A. Prince, J. C. G. Blanco. (2008) Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats. Journal of General Virology 89:1, 261-270
CrossRef136
Mark L. Everard. 2008. Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease. , 491-499.
CrossRef137
I. J. CLIFTON, J. A. KASTELIK, D. G. PECKHAM, A. HALE, M. DENTON, C. ETHERINGTON, S. P. CONWAY. (2008) Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiology and Infection 136:01,
CrossRef138
Jan ter Meulen. (2007) Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opinion on Emerging Drugs 12:4, 525-540
CrossRef139
Kelly J. Henrickson, Caroline Breese Hall. (2007) Diagnostic Assays for Respiratory Syncytial Virus Disease. The Pediatric Infectious Disease Journal 26:Supplement, S36-S40
CrossRef140
Treanor, John D., . (2007) Influenza — The Goal of Control. New England Journal of Medicine 357:14, 1439-1441
Full Text141
Cathy A. Petti, David Hillyard. (2007) Value of RVP in clinical settings: older adults. Journal of Clinical Virology 40, S53-S54
CrossRef142
D. M. FLEMING, A. J. ELLIOT, K. W. CROSS. (2007) Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods. Epidemiology and Infection 135:07,
CrossRef143
José María Navarro-Marí, Mercedes Pérez-Ruiz. (2007) Virus respiratorios: viejos y nuevos virus. Revisión de métodos diagnósticos. Enfermedades Infecciosas y Microbiología Clínica 25, 60-65
CrossRef144
Francisco López-Medrano, Jose M. Aguado, Manuel Lizasoain, Dolores Folgueira, Rafael San Juan, Carmen Díaz-Pedroche, Carlos Lumbreras, Jose M. Morales, Juan F. Delgado, Enrique Moreno-González. (2007) Clinical Implications of Respiratory Virus Infections in Solid Organ Transplant Recipients: A Prospective Study. Transplantation 84:7, 851-856
CrossRef145
Matthew B. Elliott, Tong Chen, Nicole B. Terio, Siew-Yen Chong, Rashed Abdullah, Amara Luckay, Michael A. Egan, Lee Anne Boutilier, Krista Melville, Robert A. Lerch, Deborah Long, John. H. Eldridge, Christopher L. Parks, Stephen A. Udem, Gerald E. Hancock. (2007) Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25:41, 7132-7144
CrossRef146
Nicola Ternette, Bettina Tippler, Klaus Überla, Thomas Grunwald. (2007) Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25:41, 7271-7279
CrossRef147
Lone Simonsen, Robert J Taylor, Cecile Viboud, Mark A Miller, Lisa A Jackson. (2007) Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. The Lancet Infectious Diseases 7:10, 658-666
CrossRef148
Elaine M. Castilow, Matthew R. Olson, Steven M. Varga. (2007) Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunologic Research 39:1-3, 225-239
CrossRef149
Yoshitaka Iwazu, Sumiko Honma, Genro Fujisawa, Kiyoko Uki, Ichiro Yanaka, Yoshiaki Sato, Mitsunobu Murata, Eiji Kusano, Yasushi Asano. (2007) Hyponatremic seizure associated with acute respiratory infection. Clinical and Experimental Nephrology 11:3, 230-234
CrossRef150
Keith D. Combrink, H. Belgin Gulgeze, Jan W. Thuring, Kuo-Long Yu, Rita L. Civiello, Yi Zhang, Bradley C. Pearce, Zhiwei Yin, David R. Langley, Kathleen F. Kadow, Christopher W. Cianci, Zhufang Li, Junius Clarke, Eugene V. Genovesi, Ivette Medina, Lucinda Lamb, Zheng Yang, Lisa Zadjura, Mark Krystal, Nicholas A. Meanwell. (2007) Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorganic & Medicinal Chemistry Letters 17:17, 4784-4790
CrossRef151
Shree R. Singh, Vida A. Dennis, Christina L. Carter, Shreekumar R. Pillai, Ayanna Jefferson, Shivendra V. Sahi, Eddie G. Moore. (2007) Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25:33, 6211-6223
CrossRef152
Xiangdong Alan Wang, Christopher W. Cianci, Kuo-Long Yu, Keith D. Combrink, Jan W. Thuring, Yi Zhang, Rita L. Civiello, Kathleen F. Kadow, Julia Roach, Zhufang Li, David R. Langley, Mark Krystal, Nicholas A. Meanwell. (2007) Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorganic & Medicinal Chemistry Letters 17:16, 4592-4598
CrossRef153
Ann R. Falsey. (2007) Community-Acquired Viral Pneumonia. Clinics in Geriatric Medicine 23:3, 535-552
CrossRef154
Hall, Caroline Breese, . (2007) Therapy for Bronchiolitis: When Some Become None. New England Journal of Medicine 357:4, 402-404
Full Text155
Lida Mohtasham, Alexander Auais, Giovanni Piedimonte. (2007) Nerve growth factor mediates steroid-resistant inflammation in respiratory syncytial virus infection. Pediatric Pulmonology 42:6, 496-504
CrossRef156
Lynette H Thomas, Jon S Friedland, Mike Sharland. (2007) Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection. Expert Review of Anti-infective Therapy 5:3, 415-425
CrossRef157
Shree R. Singh, Vida A. Dennis, Christina L. Carter, Shreekumar R. Pillai, Eddie G. Moore. (2007) Respiratory Syncytial Virus Recombinant F Protein (Residues 255–278) Induces a Helper T Cell Type 1 Immune Response in Mice. Viral Immunology 20:2, 261-275
CrossRef158
Stephen P. Burns. (2007) Acute Respiratory Infections in Persons with Spinal Cord Injury. Physical Medicine and Rehabilitation Clinics of North America 18:2, 203-216
CrossRef159
L. A. Mandell, R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, D. M. Musher, M. S. Niederman, A. Torres, C. G. Whitney. (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases 44:Supplement 2, S27-S72
CrossRef160
Patrick Mallia, Sebastian L Johnston. (2007) Influenza infection and COPD. International Journal of COPD 2:1, 55-64
CrossRef161
William J Doyle, Cuneyt M Alper. (2007) Use of diagnostic algorithms and new technologies to study the incidence and prevalence of viral upper respiratory tract infections and their complications in high risk populations. Current Opinion in Allergy and Clinical Immunology 7:1, 11-16
CrossRef162
Kuo-Long Yu, Ny Sin, Rita L. Civiello, X. Alan Wang, Keith D. Combrink, H. Belgin Gulgeze, Brian L. Venables, J.J. Kim Wright, Richard A. Dalterio, Lisa Zadjura, Anthony Marino, Sandra Dando, Celia D’Arienzo, Kathleen F. Kadow, Christopher W. Cianci, Zhufang Li, Junius Clarke, Eugene V. Genovesi, Ivette Medina, Lucinda Lamb, Richard J. Colonno, Zheng Yang, Mark Krystal, Nicholas A. Meanwell. (2007) Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. Bioorganic & Medicinal Chemistry Letters 17:4, 895-901
CrossRef163
Takahiko Horiguchi, Daisuke Ohira, Kashin Kobayashi, Masahiro Hirose, Junichi Miyazaki, Rieko Kondo, Soichi Tachikawa. (2007) Clinical Evaluation of Leukotriene Receptor Antagonists in Preventing Common Cold-like Symptoms in Bronchial Asthma Patients. Allergology International 56:3, 263-267
CrossRef164
John P. Mullooly, Carolyn B. Bridges, William W. Thompson, Jufu Chen, Eric Weintraub, Lisa A. Jackson, Steve Black, David K. Shay. (2007) Influenza- and RSV-associated hospitalizations among adults. Vaccine 25:5, 846-855
CrossRef165
Herman J. Bueving, Johannes C. Wouden. (2007) What is the role of virus vaccination in patients with asthma?. Current Allergy and Asthma Reports 7:1, 72-76
CrossRef166
Ann R. Falsey, Harjot K. Singh, Edward E. Walsh. (2006) Serum antibody decay in adults following natural respiratory syncytial virus infection. Journal of Medical Virology 78:11, 1493-1497
CrossRef167
Martin L. Moore, R. Stokes Peebles. (2006) Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacology & Therapeutics 112:2, 405-424
CrossRef168
Alicia M Fry, Aaron T. Curns, Kathryn Harbour, Lori Hutwagner, Robert C. Holman, Larry J. Anderson. (2006) Seasonal Trends of Human Parainfluenza Viral Infections: United States, 1990–2004. Clinical Infectious Diseases 43:8, 1016-1022
CrossRef169
James W. Matheson, Fenella J. Rich, Catherine Cohet, Keith Grimwood, Q. Sue Huang, David Penny, Michael D. Hendy, Joanna R. Kirman. (2006) Distinct patterns of evolution between respiratory syncytial virus subgroups A and B From New Zealand isolates collected over thirty-seven years. Journal of Medical Virology 78:10, 1354-1364
CrossRef170
Frances M. Weaver, Bridget Smith, Charlesnika T. Evans, Jibby E. Kurichi, Nayna Patel, Vishesh K. Kapur, Stephen P. Burns. (2006) Outcomes of Outpatient Visits for Acute Respiratory Illness in Veterans With Spinal Cord Injuries and Disorders. American Journal of Physical Medicine & Rehabilitation 85:9, 718-726
CrossRef171
Ghinwa Dumyati. 2006. Influenza and Other Respiratory Viruses. , 191-214.
CrossRef172
Charles-Edouard Luyt. (2006) Virus diseases in ICU patients: a long time underestimated; but be aware of overestimation. Intensive Care Medicine 32:7, 968-970
CrossRef173
Asunción Mejías, Octavio Ramilo. (2006) New approaches to reduce the burden of RSV infection. Drug Discovery Today: Therapeutic Strategies 3:2, 173-181
CrossRef174
R. Ortiz de Lejarazu, J.M. Eiros, I. Gracia. (2006) Gripe y viriasis respiratorias. Medicine - Programa de Formación Médica Continuada Acreditado 9:59, 3820-3829
CrossRef175
Andreas Jung, Shizuo Akira. (2006) Toll-like receptors in antiviral immunity: more than just response. Future Virology 1:3, 313-316
CrossRef176
Punam Mangtani, Shakoor Hajat, Sari Kovats, Paul Wilkinson, Ben Armstrong. (2006) The Association of Respiratory Syncytial Virus Infection and Influenza with Emergency Admissions for Respiratory Disease in London: An Analysis of Routine Surveillance Data. Clinical Infectious Diseases 42:5, 640-646
CrossRef177
Kuo-Long Yu, Xiangdong Alan Wang, Rita L. Civiello, Ashok K. Trehan, Bradley C. Pearce, Zhiwei Yin, Keith D. Combrink, H. Belgin Gulgeze, Yi Zhang, Kathleen F. Kadow, Christopher W. Cianci, Junius Clarke, Eugene V. Genovesi, Ivette Medina, Lucinda Lamb, Philip R. Wyde, Mark Krystal, Nicholas A. Meanwell. (2006) Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorganic & Medicinal Chemistry Letters 16:5, 1115-1122
CrossRef178
Jay H Ryu. (2006) Classification and approach to bronchiolar diseases. Current Opinion in Pulmonary Medicine 12:2, 145-151
CrossRef179
T.E. McManus, P.V. Coyle, J.C. Kidney. (2006) Childhood respiratory infections and hospital admissions for COPD. Respiratory Medicine 100:3, 512-518
CrossRef180
Mark L. Everard. (2006) The role of the respiratory syncytial virus in airway syndromes in childhood. Current Allergy and Asthma Reports 6:2, 97-102
CrossRef181
A. R. Falsey, E. E. Walsh. (2006) Viral Pneumonia in Older Adults. Clinical Infectious Diseases 42:4, 518-524
CrossRef182
Mark L Everard. (2006) The relationship between respiratory syncytial virus infections and the development of wheezing and asthma in children. Current Opinion in Allergy and Clinical Immunology 6:1, 56-61
CrossRef183
Fabrice Carrat, Marianne Leruez-Ville, Marc Tonnellier, Jean-Luc Baudel, Juliette Deshayes, Pascal Meyer, Eric Maury, Julie Galimand, Christine Rouzioux, Georges Offenstadt. (2006) A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Medicine 32:1, 156-159
CrossRef184
Weidong Zhang, Richard F Lockey, Shyam S Mohapatra. (2006) Respiratory syncytial virus: immunopathology and control. Expert Review of Clinical Immunology 2:1, 169-179
CrossRef185
Asunci??n Mej??as, Susana Ch??vez-Bueno, Hasan S. Jafri, Octavio Ramilo. (2005) Respiratory Syncytial Virus Infections: Old Challenges and New Opportunities. The Pediatric Infectious Disease Journal 24:Supplement, S189-S197
CrossRef186
(2005) Respiratory Syncytial Virus Infection in Elderly Adults. New England Journal of Medicine 353:4, 422-423
Full Text187
Sethi, Sanjay, Murphy, Timothy F., . (2005) RSV Infection — Not for Kids Only. New England Journal of Medicine 352:17, 1810-1812
Full Text188
Ann R Falsey, Edward E Walsh. (2005) Respiratory Syncytial Virus Infection in Elderly Adults. Drugs & Aging 22:7, 577-587
CrossRef
- Letters
